Related Experiment Video
Updated: May 23, 2026
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients
Peter Arne Gerber1, Stephan Meller, Tatiana Eames
1Department of Dermatology, University of Duesseldorf, Medical Faculty, Moorenstrasse 5, D-40225 Duesseldorf, Germany. peterarne.gerber@uni-duesseldorf.de
Background:
In recent years inhibitors directed against the epidermal growth factor receptor (EGFR) have evolved as effective targeting cancer drugs. Characteristic papulopustular exanthemas, often described as acneiform rashes, are the most frequent adverse effect associated with this class of novel cancer drugs and develop in > 90% of patients. Notably, the rash may significantly compromise the patients' quality of life, thereby potentially leading to incompliance as well as dose reduction or even termination of the anti-EGFR therapy. Yet, an effective dermatologic management of cutaneous adverse effects can be achieved. Whereas various case reports, case series or expert opinions on the management of EGFR-inhibitor (EGFRI) induced rashes have been published, data on systematic management studies are sparse.
Methods:
Here, we present a retrospective, uncontrolled, comparative study in 49 patients on three established regimens for the management of EGFRI-associated rashes.
Results:
Strikingly, patients' rash severity improved significantly over three weeks of treatment with topical mometason furoate cream, topical prednicarbate cream plus nadifloxacin cream, as well as topical prednicarbate cream plus nadifloxacin cream plus systemic isotretinoin.
Conclusions:
In summary our results demonstrate that EGFRI-associated rashes can be effectively managed by specific dermatologic interventions. Whereas mild to moderate rashes should be treated with basic measures in combination with topical glucocorticosteroids or combined regiments using glucocorticosteroids and antiseptics/antibiotics, more severe or therapy-resistant rashes are likely to respond with the addition of systemic retinoids.
Insights
Epidermal growth factor receptor (EGFR) inhibitor-associated rashes significantly impact cancer patients. Effective dermatologic management, including topical treatments and systemic retinoids for severe cases, improves rash severity and patient compliance.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) inhibitors are crucial targeted cancer therapies.
- Acneiform rashes affect over 90% of patients, potentially compromising quality of life and treatment adherence.
- Systematic studies on managing these EGFR-inhibitor (EGFRI)-induced rashes are limited.
Purpose of the Study:
- To evaluate the effectiveness of three established dermatologic regimens for managing EGFRI-associated rashes.
- To provide data supporting systematic management strategies for these common adverse effects.
Main Methods:
- A retrospective, uncontrolled, comparative study involving 49 patients.
- Assessment of three distinct treatment regimens for EGFRI-induced cutaneous adverse effects.
Main Results:
- All three treatment regimens led to significant improvements in rash severity within three weeks.
- Topical mometason furoate, topical prednicarbate with nadifloxacin, and topical prednicarbate with nadifloxacin plus systemic isotretinoin were effective.
- Addition of systemic retinoids showed promise for severe or resistant cases.
Conclusions:
- EGFRI-associated rashes can be effectively managed with specific dermatologic interventions.
- Mild to moderate rashes benefit from basic measures, topical glucocorticosteroids, or combined antiseptic/antibiotic therapies.
- Severe or therapy-resistant rashes may require the addition of systemic retinoids for optimal outcomes.
